ArticleDrug and alcohol dependence2026
Impact of Medicaid waivers on medication for opioid use disorders in residential facilities: Evidence from twenty-five states.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMedicaid Section 1115 waivers allow states to test demonstration programs with the potential to shape access to care for millions of beneficiaries. The Institutions for Mental Diseases (IMD) waiver enables states to use federal funds to treat substance use disorders in residential facilities, bypassing Medicaid's long-standing IMD exclusion. We assessed the impact of IMD waiver adoption on the use of medication for opioid use disorder (MOUD) by estimating cohort-specific effects among four groups of states that adopted waivers between 2016 and 2019.
methodsWe used Treatment Episode Data Set data. Data on the outcome, i.e., MOUD use among opioid-involved treatment episodes, and covariates were linked to data on waiver effective date, extracted from waiver approval documents. We used difference-in-differences to estimate models stratified by treatment setting (residential vs. non-residential) and adjusted for state-level policy indicators, and state- and year-fixed effects.
resultsMOUD use was low, especially among residential admissions, but increased over time from 5% in 2014-18% in 2019. In adjusted models, the cohort of states that adopted a waiver in 2016 showed higher odds of MOUD use in residential settings (OR=1.49, 95% CI: 1.21-1.84) relative to the comparison group. However, this pattern was not replicated for the later cohorts. Finally, waiver adoption did not have an impact on MOUD use in non-residential settings.
conclusionIn early adopter states, IMD waivers might have facilitated MOUD use in residential facilities, but their effects varied across cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.